Breaking News, Collaborations & Alliances

Evelo, Merck Enter Clinical Trial Collaboration

To evaluate EDP1503 in combination with Keytruda, Merck’s anti-PD-1 therapy, in multiple cancer indications

Evelo Biosciences has entered into a clinical trial collaboration agreement with Merck. The collaboration will evaluate EDP1503 in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in multiple cancer indications. EDP1503 is an orally delivered monoclonal microbial product candidate being developed for the treatment of cancer. The planned Phase 1/2 trial will evaluate the safety, tolerability, immune response markers and overall response rates (ORRs) achieved with EDP15...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters